Celecoxib sensitizes Staphylococcus aureus to antibiotics in macrophages by modulating SIRT1

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Annamanedi, Madhavi ^a   Kalle, Arunasree M ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CATALASE; CELECOXIB; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NITRIC OXIDE; PEROXIDASE; SIRTUIN 1; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2; ANTIINFECTIVE AGENT; PYRAZOLE DERIVATIVE; SIRT1 PROTEIN, MOUSE; SULFONAMIDE;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASSAY; BACTERIAL LOAD; CONTROLLED STUDY; COX 2 GENE; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ENZYME STABILITY; FLUORESCENCE ACTIVATED CELL SORTING; INFLAMMATION; MACROPHAGE; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; INFLAMMATION; MACROPHAGES; MICE; NITRIC OXIDE; OXIDATIVE STRESS; PYRAZOLES; SIGNAL TRANSDUCTION; SIRTUIN 1; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SULFONAMIDES;

EID: 84903390247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099285     Document Type: Article

References (39)

1. Kalle AM, Rizvi A (2011) Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob Agents Chemother 55: 439-442.
2. Ejim L, Farha MA, Falconer SB, Wildenhain J, Coombes BK, et al. (2010) Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol.
3. Zhang Z, Lowry SF, Guarente L, Haimovich B (2010) Roles of SIRT1 in the acute and restorative phases following induction of inflammation. J Biol Chem 285: 41391-41401.
4. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, et al. (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9: 327-338.
5. Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Isshiki K, et al. (2010) Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 120: 1043-1055.
6. Chen CJ, Yu W, Fu YC, Wang X, Li JL, et al. (2009) Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun 378: 389-393.
7. Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW, et al. (2010) Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol Cell Biol 30: 4712-4721.
8. Zhang R, Chen HZ, Liu JJ, Jia YY, Zhang ZQ, et al. (2010) SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem 285: 7097-7110.
9. Koziel J, Maciag-Gudowska A, Mikolajczyk T, Bzowska M, Sturdevant DE, et al. (2009) Phagocytosis of Staphylococcus aureus by macrophages exerts cytoprotective effects manifested by the upregulation of antiapoptotic factors. PLoS One 4: e5210.
10. Palladino MA, Johnson TA, Gupta R, Chapman JL, Ojha P (2007) Members of the Toll-like receptor family of innate immunity pattern-recognition receptors are abundant in the male rat reproductive tract. Biol Reprod 76: 958-964. (Pubitemid 46835003)
11. Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, et al. (2008) Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res 32: 855-864.
12. Caito S, Rajendrasozhan S, Cook S, Chung S, Yao H, et al. (2010) SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J 24: 3145-3159.
13. Lefebre M, Valvano M (2001) In vitro resistance of Burkholderia cepacia complex isolates to reactive oxygen species in relation to catalase and superoxide dismutase production. Microbiology 147: 97-109. (Pubitemid 32094313)
14. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, et al. (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126: 131-138. (Pubitemid 13203451)
15. Hojgard S (2012) Antibiotic resistance - why is the problem so difficult to solve? Infect Ecol Epidemiol 2.
16. Ruof J, Hulsemann JL (2000) [Cyclooxygenase-2 (Cox-2) selective inhibitors: socioeconomic and pharmaco-epidemiologic aspects]. Z Rheumatol 59: 124-127.
17. Gajraj NM (2007) COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management. Curr Top Med Chem 7: 235-249.
18. Howes LG (2007) Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther Clin Risk Manag 3: 831-845.
19. Stables MJ, Newson J, Ayoub SS, Brown J, Hyams CJ, et al. (2010) Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood 116: 2950-2959.
20. Rahman I, Kinnula VL, Gorbunova V, Yao H (2012) SIRT1 as a therapeutic target in inflammaging of the pulmonary disease. Prev Med 54 Suppl: S20-28.
21. Zhang Z, Lowry SF, Guarente L, Haimovich B (2010) Roles of SIRT1 in the acute and restorative phases following induction of inflammation. J Biol Chem 285: 41391-41401.
22. Lee JH, Song MY, Song EK, Kim EK, Moon WS, et al. (2009) Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 58: 344-351.
23. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, et al. (2010) SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 298: E419-428.
24. Zhang R, Chen HZ, Liu JJ, Jia YY, Zhang ZQ, et al. (2010) SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem 285: 7097-7110.
25. Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR, et al. (2009) Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 380: 644-649.
26. Pietrocola G, Arciola CR, Rindi S, Di Poto A, Missineo A, et al. (2011) Toll-like receptors (TLRs) in innate immune defense against Staphylococcus aureus. Int J Artif Organs 34: 799-810.
27. Iyori M, Kataoka H, Shamsul HM, Kiura K, Yasuda M, et al. (2008) Resveratrol modulates phagocytosis of bacteria through an NF-kappaB-dependent gene program. Antimicrob Agents Chemother 52: 121-127.
28. Wu JT, Kral JG (2005) The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 123: 158-169. (Pubitemid 40094658)
29. Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cancer. Virchows Arch 446: 475-482. (Pubitemid 40884279)
30. Shakibaei M, Buhrmann C, Mobasheri A (2011) Resveratrol-mediated SIRT-1 Interactions with p300 Modulate Receptor Activator of NF-{kappa}B Ligand (RANKL) Activation of NF-{kappa}B Signaling and Inhibit Osteoclastogenesis in Bone-derived Cells. J Biol Chem 286: 11492-11505.
31. Shakibaei M, Harikumar KB, Aggarwal BB (2009) Resveratrol addiction: to die or not to die. Mol Nutr Food Res 53: 115-128.
32. Csaki C, Mobasheri A, Shakibaei M (2009) Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 11: R165.
33. Shakibaei M, Csaki C, Nebrich S, Mobasheri A (2008) Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 76: 1426-1439.
34. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M (2008) Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol 75: 677-687.
35. Shakibaei M, John T, Seifarth C, Mobasheri A (2007) Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann N Y Acad Sci 1095: 554-563. (Pubitemid 47092487)
36. Verdin E (2007) AROuSing SIRT1: identification of a novel endogenous SIRT1 activator. Mol Cell 28: 354-356.
37. Knutson MD, Leeuwenburgh C (2008) Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 66: 591-596.
38. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716. (Pubitemid 350207685)
39. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, et al. (2004) Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 16: 93-105. (Pubitemid 39330155)